Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
Amit M OzaDomenica LorussoCarol AghajanianAna OakninAndrew DeanNicoletta ColomboJohanne I WeberpalsAndrew R ClampGiovanni ScambiaAlexandra LearyRobert W HollowayMargarita Amenedo GancedoPeter C FongJeffrey C GohDavid M O'MalleyDeborah K ArmstrongSusana BanerjeeJesús García-DonasElizabeth M SwisherDavid CellaJuliette MeunierSandra GobleTerri CameronLara MaloneyAnn-Christin MörkJosh BedelJonathan A LedermannRobert L ColemanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
The significant differences in QA-PFS and Q-TWiST confirm the benefit of rucaparib versus placebo in all predefined cohorts.